The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers
Authors:
- 1 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (2) , 265-270
Abstract
HIV protease inhibitors have been shown to worsen glucose and lipid metabolism. Recent studies have suggested that protease inhibitors can impair insulin secretion in HIV-infected patients. We studied the effects of the protease inhibitor combination lopinavir and ritonavir on insulin secretion, insulin sensitivity, and lipid metabolism in HIV-negative persons. A combination dose of lopinavir 400 mg and ritonavir 100 mg was given twice daily to eight HIV-seronegative men for 4 weeks. Fasting glucose, insulin, lipid, and lipoprotein profiles; oral glucose tolerance; insulin secretion and insulin-mediated glucose disposal by hyperglycemic clamp; and body composition by dual energy X-ray absorptiometry were determined before and after lopinavir/ritonavir administration. There was no change in first-phase insulin secretion (2.82 ± 0.30 versus 2.71 ± 0.31 nmol/l; P = 0.60), as well as fasting insulin and glucose levels, oral glucose tolerance, or insulin-mediated glucose disposal after 4 weeks administration of lopinavir/ritonavir. However, there were significant increases in fasting triglycerides (1.02 ± 0.13 versus 2.20 ± 0.31 mmol/l; P = 0.001), total cholesterol (4.42 ± 0.30 versus 5.70 ± 0.60 mmol/l; P = 0.007), and apo B-100 levels (0.86 ± 0.07 versus 1.07 ± 0.11 g/l; P = 0.0009). High-density lipoprotein cholesterol decreased (0.99 ± 0.11 versus 0.82 ± 0.10 mmol/l; P = 0.005). There were no changes in body composition, weight, or body fat. Although administration of lopinavir/ritonavir to healthy, HIV-seronegative volunteers for 4 weeks resulted in increased triglyceride and decreased high-density lipoprotein cholesterol levels, there was no change in first-phase insulin secretion during the hyperglycemic clamp. The reported effects of protease inhibitor on insulin secretion in HIV-infected individuals may be due to changes in HIV-related factors and not a direct drug effect.Keywords
This publication has 19 references indexed in Scilit:
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteersAIDS, 2007
- Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinicallyAIDS, 2006
- Single‐Dose Lopinavir‐Ritonavir Acutely Inhibits Insulin‐Mediated Glucose Disposal in Healthy VolunteersClinical Infectious Diseases, 2006
- Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort StudyArchives of internal medicine (1960), 2005
- Prospective, Intensive Study of Metabolic Changes Associated with 48 Weeks of Amprenavir‐Based Antiretroviral TherapyClinical Infectious Diseases, 2002
- Prospective Evaluation of the Effect of Initiating Indinavir-Based Therapy on Insulin Sensitivity and B-Cell Function in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Prospective Evaluation of the Effect of Initiating Indinavir-Based Therapy on Insulin Sensitivity and B-Cell Function in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn StudyDiabetologia, 1996
- Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection.Journal of Clinical Investigation, 1995